Kennametal (KMT) Beats Q3 Earnings Estimates
Kennametal (KMT) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.30 per share a year ago.
Reasons Why You Should Avoid Betting on Kennametal Stock Now
Weakness in the operating segments weighs on KMT's performance. An increase in operating expenses is an added concern.
Kennametal: Visible Near-Term Weakness
I assign a hold rating to Kennametal stock due to ongoing weakness in its Metal Cutting segment and lack of near-term recovery catalysts. KMT's 2Q25 earnings report shows continued declines in revenue and organic growth, with significant deterioration in the Metal Cutting segment. Management's downward revision of FY25 guidance underscores poor demand trends, making a near-term turnaround unlikely.
Kennametal's Q2 Earnings Match Estimates, Revenues Decline Y/Y
KMT's fiscal second-quarter 2025 revenues decrease 2.7% due to the lackluster performance of the Metal Cutting segment.
Kennametal Inc. (KMT) Q2 2025 Earnings Call Transcript
Kennametal Inc. (KMT) Q2 2025 Earnings Call Transcript
Kennametal (KMT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Kennametal (KMT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kennametal (KMT) Matches Q2 Earnings Estimates
Kennametal (KMT) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago.
Here's Why Investors Should Retain Kennametal Stock Right Now
KMT benefits from strength in the Infrastructure unit, diversified product portfolio and shareholder-friendly policies. However, softness in the Metal Cutting segment remains concerning.
Here's Why You Should Retain Kennametal Stock in Your Portfolio
KMT is set to benefit from strong momentum in the Infrastructure segment. The company's measures to reward its shareholders are also encouraging.
Why Is Kennametal (KMT) Down 5% Since Last Earnings Report?
Kennametal (KMT) reported earnings 30 days ago. What's next for the stock?
Kennametal Stock Exhibits Strong Prospects Despite Headwinds
KMT is set to benefit from strong momentum in the Infrastructure segment. However, increasing costs and expenses remain a concern.
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Primary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action date of December 26th of 2024 deployed for FDA to decide if Revumenib should be approved for the treatment of relapsed/refractory KMT2Ar Acute leukemia patients. The global acute myeloid leukemia market is expected to reach $5.86 billion by 2030; About 10% of patients have KMT2Ar AML and then 30% have mNPM1 AML.
